KEMPHARM INC (KMPH)

US4884452065 - Common Stock

5.81  -0.02 (-0.34%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

KEMPHARM INC

NASDAQ:KMPH (2/28/2023, 7:00:03 PM)

5.81

-0.02 (-0.34%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap200.47M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KMPH Daily chart

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 24 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The firm also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.

Company Info

KEMPHARM INC

1180 Celebration Blvd Ste 103

Celebration FLORIDA 34747

P: 13219393416.0

CEO: Travis C. Mickle

Employees: 24

Website: http://www.kempharm.com/

KMPH News

News Imagea year ago - Zevra TherapeuticsZevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm,...

News Imagea year ago - Zevra TherapeuticsZevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare...

News Imagea year ago - Zevra TherapeuticsZevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of...

News Imagea year ago - KemPharmZevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare...

News Imagea year ago - KemPharmCORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
News Imagea year ago - KemPharmCORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics

New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to...

KMPH Twits

Here you can normally see the latest stock twits on KMPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example